Incyte
CompanyUnited StatesFounded 2001
Incyte develops 13 assets, the furthest approved (baricitinib in Active Rheumatoid Arthritis). Mostly small molecule and antibody acting on PDCD1, JAK2 and JAK1; based in the United States, founded in 2001.
- 13
- Assets
- Furthest stage
- Approved
- 181
- Trials
- 38
- Signals
Pipeline
13Selective JAK1 and JAK2 inhibitor that reduces inflammatory signaling pathways.
Approved, Small molecule, JAK2, JAK1, Active Rheumatoid Arthritis, rheumatoid arthritis, Partner
Blocks colony stimulating factor-1 receptor signaling to reduce pathogenic macrophage activity in chronic graft-versus-host disease.
Approved, Antibody, CSF1R, chronic graft versus host disease, idiopathic pulmonary fibrosis (Phase 2)
Inhibits BCR-ABL kinase, including the T315I resistance mutant, to suppress leukemic cell growth.
Approved, Small molecule, BCR, ABL1, Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia, chronic myeloid leukemia
10 more assets
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms9
- Trials332
- Deals8
- People18
- Signals20
- Similar companies6
Papers
Therapeutic advances in hematology, Mar 27, 2026
A proposed path to explaining the unexplained anemia of aging
The journals of gerontology. Series A, Biological sciences and medical sciences, Nov 9, 2025
Ageing research reviews, Nov 5, 2017